Metformin treatment of patients with hand osteoarthritis: A randomised, placebo-controlled trial

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2023-509181-38-00

Enrollment

150

Registered

2024-04-11

Start date

2024-05-03

Completion date

Unknown

Last updated

2025-06-12

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Osteoarthritis

Brief summary

Change from baseline in VAS finger joint pain of the target hand after 16 weeks of treatment (at the week 17 visit).

Interventions

DRUGThe placebo is produced by the central pharmacy of the capital region in Denmark. The placebo contains no active ingrediens.

DRUGMetformin Orifarm 500 mg filmdragerade tabletter

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
Change from baseline in VAS finger joint pain of the target hand after 16 weeks of treatment (at the week 17 visit).	—

Countries

Denmark

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026